US20140309164A1 - Deuterated nucleoside prodrugs useful for treating hcv - Google Patents
Deuterated nucleoside prodrugs useful for treating hcv Download PDFInfo
- Publication number
- US20140309164A1 US20140309164A1 US14/252,494 US201414252494A US2014309164A1 US 20140309164 A1 US20140309164 A1 US 20140309164A1 US 201414252494 A US201414252494 A US 201414252494A US 2014309164 A1 US2014309164 A1 US 2014309164A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- compound
- deuterium
- hydrogen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1C([1*])([2*])C(B)OC1([3*])C([4*])([5*])OP(=O)(O[6*])[Y]C([7*])([8*])C(=O)O[9*] Chemical compound *C1C([1*])([2*])C(B)OC1([3*])C([4*])([5*])OP(=O)(O[6*])[Y]C([7*])([8*])C(=O)O[9*] 0.000 description 26
- FANHNUUIFWJLEE-PZUNWCBCSA-N C=CC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC(C3=CC=CC=C3)=NC3=C2C=CC(OC)=C3)CN1C(=O)[C@@H](CC(=O)N1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1.[H][C@]12/C=C\CCCCC[C@H](CC(=O)N3CCCC(F)(F)C3)C(=O)N3C[C@H](OC4=C5C=CC(OC)=C(C)C5=NC(C5=NC(C(C)C)=CS5)=C4)C[C@H]3C(=O)C[C@]1(C(=O)NS(=O)(=O)C1CC1)C2 Chemical compound C=CC1C[C@]1(NC(=O)[C@@H]1C[C@@H](OC2=CC(C3=CC=CC=C3)=NC3=C2C=CC(OC)=C3)CN1C(=O)[C@@H](CC(=O)N1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1.[H][C@]12/C=C\CCCCC[C@H](CC(=O)N3CCCC(F)(F)C3)C(=O)N3C[C@H](OC4=C5C=CC(OC)=C(C)C5=NC(C5=NC(C(C)C)=CS5)=C4)C[C@H]3C(=O)C[C@]1(C(=O)NS(=O)(=O)C1CC1)C2 FANHNUUIFWJLEE-PZUNWCBCSA-N 0.000 description 2
- PEKAGZSOUWHCLK-UHFFFAOYSA-N CC1=C(Cl)C=C(S)C(Cl)=C1.CC1=CC=C(O)N=C1.CC1=CC=C(S)C=C1.CC1=CC=C(S)C=C1.FC1=C(F)C(F)=C(S)C(F)=C1F.O=C1C2=C(C=CC=C2)C(=O)N1O.O=C1CCC(=O)N1O Chemical compound CC1=C(Cl)C=C(S)C(Cl)=C1.CC1=CC=C(O)N=C1.CC1=CC=C(S)C=C1.CC1=CC=C(S)C=C1.FC1=C(F)C(F)=C(S)C(F)=C1F.O=C1C2=C(C=CC=C2)C(=O)N1O.O=C1CCC(=O)N1O PEKAGZSOUWHCLK-UHFFFAOYSA-N 0.000 description 2
- ZGJNEXAVRJJVBN-PWFNWSNSSA-N CC1=C(Cl)C=C(S[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)C(Cl)=C1 Chemical compound CC1=C(Cl)C=C(S[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)C(Cl)=C1 ZGJNEXAVRJJVBN-PWFNWSNSSA-N 0.000 description 2
- YHFSTBCXFWKFPJ-ADHPNMQSSA-N COC(=O)N[C@H](C(=O)N1CCC[C@H]1C1=NC2=C(C=CC(C3=CC4=CC=C3CCC3=CC(C5=CC6=C(C=C5)NC([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)=N6)=C(C=C3)CC4)=C2)N1)C(C)C.COC(=O)N[C@H](C(=O)N1[C@H](C2=NC3=C(C=CC(C4=CC5=CC=C4CCC4=CC(C6=CC7=C(C=C6)NC([C@@H]6C[C@@H]8CCCC[C@@H]8N6C(=O)[C@@H](NC(=O)OC)C(C)C)=N7)=C(C=C4)CC5)=C3)N2)C[C@@H]2CCCC[C@@H]21)C(C)C Chemical compound COC(=O)N[C@H](C(=O)N1CCC[C@H]1C1=NC2=C(C=CC(C3=CC4=CC=C3CCC3=CC(C5=CC6=C(C=C5)NC([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)=N6)=C(C=C3)CC4)=C2)N1)C(C)C.COC(=O)N[C@H](C(=O)N1[C@H](C2=NC3=C(C=CC(C4=CC5=CC=C4CCC4=CC(C6=CC7=C(C=C6)NC([C@@H]6C[C@@H]8CCCC[C@@H]8N6C(=O)[C@@H](NC(=O)OC)C(C)C)=N7)=C(C=C4)CC5)=C3)N2)C[C@@H]2CCCC[C@@H]21)C(C)C YHFSTBCXFWKFPJ-ADHPNMQSSA-N 0.000 description 2
- IJLDVICLPJUPDL-NKMPLPLHSA-M *.B.C.C.[2HH].[2H]C([2H])(O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(OP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(OP(=O)([O-])O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1OC(N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O Chemical compound *.B.C.C.[2HH].[2H]C([2H])(O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(OP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(OP(=O)([O-])O)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1OC(N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O IJLDVICLPJUPDL-NKMPLPLHSA-M 0.000 description 1
- BCLDCVPXTJHZRV-REOZUEICSA-N C.C.C.C.C.C.C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC(=O)OC(C)=O.CC(C)(C)OC(=O)[C@H]1OC(N2C=CcnC2=O)[C@]2(C)OC(C)(C)O[C@H]12.CC(C)OC(=O)[C@H](C)N[P@](C)(=O)OC1=CC=CC=C1.CC1(C)O[C@@H]2[C@@H](CO)OC(N3C=CcnC3=O)[C@]2(C)O1.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.COC(C)(C)C.C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CcnC1=O.N=N/N=N/Cl.O=C1ncC=CN1.[2H]C([2H])(O)[C@H]1OC(N2C=CcnC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O)[C@H]1OC(N2C=CcnC2=O)[C@]2(C)OC(C)(C)O[C@H]12 Chemical compound C.C.C.C.C.C.C.C.C.C.C.C.C.CC.CC.CC.CC.CC.CC.CC(=O)OC(C)=O.CC(C)(C)OC(=O)[C@H]1OC(N2C=CcnC2=O)[C@]2(C)OC(C)(C)O[C@H]12.CC(C)OC(=O)[C@H](C)N[P@](C)(=O)OC1=CC=CC=C1.CC1(C)O[C@@H]2[C@@H](CO)OC(N3C=CcnC3=O)[C@]2(C)O1.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.COC(C)(C)C.C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CcnC1=O.N=N/N=N/Cl.O=C1ncC=CN1.[2H]C([2H])(O)[C@H]1OC(N2C=CcnC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O)[C@H]1OC(N2C=CcnC2=O)[C@]2(C)OC(C)(C)O[C@H]12 BCLDCVPXTJHZRV-REOZUEICSA-N 0.000 description 1
- XRRWWTZCZILZGI-QLWNWKBNSA-N C.C.C.C.C.C.C.C.C.C.CC(=O)OC(C)=O.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.COC(C)(C)C.ClCCl.N=N/N=N/Cl.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C(=O)OC(C)(C)C)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C([2H])([2H])O)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](CO)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])OP(=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C)C(=O)NC(=O)N1.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@]1(C)O Chemical compound C.C.C.C.C.C.C.C.C.C.CC(=O)OC(C)=O.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.COC(C)(C)C.ClCCl.N=N/N=N/Cl.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C(=O)OC(C)(C)C)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](C([2H])([2H])O)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1C1O[C@H](CO)[C@H]2OC(C)(C)O[C@@]12C.[2H]C1=C(C([2H])([2H])[2H])C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])OP(=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C)C(=O)NC(=O)N1.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@]1(C)O XRRWWTZCZILZGI-QLWNWKBNSA-N 0.000 description 1
- FSTIWTIQDPCGSL-HSCPHAFYSA-N C.C.C.C.C.C.C.CC(C)(C)OC(=O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@]2(C)OC(C)(C)O[C@H]12.CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.O.[2H]C([2H])(O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@]2(C)OC(C)(C)O[C@H]12.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O Chemical compound C.C.C.C.C.C.C.CC(C)(C)OC(=O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@]2(C)OC(C)(C)O[C@H]12.CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.O.[2H]C([2H])(O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@]2(C)OC(C)(C)O[C@H]12.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O FSTIWTIQDPCGSL-HSCPHAFYSA-N 0.000 description 1
- WVVUCIQXWBIQMD-TUPSUHJASA-N C.C.C.C.CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.[2H]C1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CNC(=O)NC1=O Chemical compound C.C.C.C.CC(C)OC(=O)[C@H](C)N[P@@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.CC[C@H]1OC(OC(=O)C2=CC=CC=C2)[C@](C)(OC(=O)C2=CC=CC=C2)[C@@H]1C.[2H]C1=CN([C@@H]2O[C@H](CO)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CNC(=O)NC1=O WVVUCIQXWBIQMD-TUPSUHJASA-N 0.000 description 1
- PWWQXSLLQQMPCN-YIQZCTNXSA-N C.C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@@]1(O)[C@H](OCC2=CC=C(Cl)C=C2Cl)[C@@H](COCC2=CC=C(Cl)C=C2Cl)O[C@H]1N1C=CC(=O)NC1=O Chemical compound C.C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@@]1(O)[C@H](OCC2=CC=C(Cl)C=C2Cl)[C@@H](COCC2=CC=C(Cl)C=C2Cl)O[C@H]1N1C=CC(=O)NC1=O PWWQXSLLQQMPCN-YIQZCTNXSA-N 0.000 description 1
- NJSCGUGKLPXUIX-XQZPJVSQSA-N C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC Chemical compound C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC NJSCGUGKLPXUIX-XQZPJVSQSA-N 0.000 description 1
- UYMFDJANLDOPRA-MHPUKMEKSA-N C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC Chemical compound C.C.CC(C)(C)[Mg]ClC1CCCO1.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC UYMFDJANLDOPRA-MHPUKMEKSA-N 0.000 description 1
- IYEJIKLHGCOQGQ-BDBSIBGWSA-N C.C.CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)NP(=S)(Cl)OC1=CC=CC=C1.CC(C)OC(=O)[C@H](C)N[P@](=S)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O)OC1=CC=CC=C1.C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.OC1=CC=CC=C1.S=P(Cl)(Cl)Cl.S=P(Cl)(Cl)OC1=CC=CC=C1 Chemical compound C.C.CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)NP(=S)(Cl)OC1=CC=CC=C1.CC(C)OC(=O)[C@H](C)N[P@](=S)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O)OC1=CC=CC=C1.C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C=CC(=O)NC1=O.OC1=CC=CC=C1.S=P(Cl)(Cl)Cl.S=P(Cl)(Cl)OC1=CC=CC=C1 IYEJIKLHGCOQGQ-BDBSIBGWSA-N 0.000 description 1
- QCJOZEFLHILZBB-NXAOXGSFSA-N C.CC(C)OC(=O)[C@H](C)N.Cl.O=P(Cl)(Cl)OC1=CC=CC=C1 Chemical compound C.CC(C)OC(=O)[C@H](C)N.Cl.O=P(Cl)(Cl)OC1=CC=CC=C1 QCJOZEFLHILZBB-NXAOXGSFSA-N 0.000 description 1
- BOUOTTINLYBKDL-LXUMTQMMSA-N C.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)SC1=CC(Cl)=C(Cl)C=C1Cl.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O Chemical compound C.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)SC1=CC(Cl)=C(Cl)C=C1Cl.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O BOUOTTINLYBKDL-LXUMTQMMSA-N 0.000 description 1
- WUKPSUNLKZISNH-OHLYEKSHSA-M C.CO[C@H]1O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@@H](OCC2=CC=C(Cl)C=C2Cl)C1=O.CO[Na].O=C(Cl)C1=CC=CC=C1.[2H]C([2H])([2H])[C@@]1(OC(=O)C2=CC=CC=C2)[C@H](OCC2=CC=C(Cl)C=C2Cl)[C@@H](COCC2=CC=C(Cl)C=C2Cl)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@]1(O)[C@@H](OC)O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@H]1OCC1=CC=C(Cl)C=C1Cl.[2H]C([2H])([2H])[C@]1(OC(=O)C2=CC=CC=C2)[C@@H](OC)O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@H]1OCC1=CC=C(Cl)C=C1Cl.[2H]C([2H])([2H])[Mg]I Chemical compound C.CO[C@H]1O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@@H](OCC2=CC=C(Cl)C=C2Cl)C1=O.CO[Na].O=C(Cl)C1=CC=CC=C1.[2H]C([2H])([2H])[C@@]1(OC(=O)C2=CC=CC=C2)[C@H](OCC2=CC=C(Cl)C=C2Cl)[C@@H](COCC2=CC=C(Cl)C=C2Cl)O[C@H]1N1C=CC(=O)NC1=O.[2H]C([2H])([2H])[C@]1(O)[C@@H](OC)O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@H]1OCC1=CC=C(Cl)C=C1Cl.[2H]C([2H])([2H])[C@]1(OC(=O)C2=CC=CC=C2)[C@@H](OC)O[C@H](COCC2=CC=C(Cl)C=C2Cl)[C@H]1OCC1=CC=C(Cl)C=C1Cl.[2H]C([2H])([2H])[Mg]I WUKPSUNLKZISNH-OHLYEKSHSA-M 0.000 description 1
- HYCALBUVEKOZAW-UHFFFAOYSA-N CC(C)(C)C12CC(C(C)(C)C)(C1)C2 Chemical compound CC(C)(C)C12CC(C(C)(C)C)(C1)C2 HYCALBUVEKOZAW-UHFFFAOYSA-N 0.000 description 1
- NUEKHFLLXSCPAI-UHFFFAOYSA-N CC(C)(C)C1=CNC(C(C)(C)C)=N1 Chemical compound CC(C)(C)C1=CNC(C(C)(C)C)=N1 NUEKHFLLXSCPAI-UHFFFAOYSA-N 0.000 description 1
- AGJWCLUZARAROD-RLYJSRSWSA-N CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.Cl.O=P(Cl)(Cl)OC1=CC=CC=C1.OC1=C(F)C(F)=C(F)C(F)=C1F Chemical compound CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=C(F)C(F)=C(F)C(F)=C1F.Cl.O=P(Cl)(Cl)OC1=CC=CC=C1.OC1=C(F)C(F)=C(F)C(F)=C1F AGJWCLUZARAROD-RLYJSRSWSA-N 0.000 description 1
- FAHWHMJUIXXQLH-NMGLKSEGSA-N CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)SC1=CC(Cl)=C(Cl)C=C1Cl.CCN(CC)CC.Cl.ClCCl.O=P(Cl)(Cl)OC1=CC=CC=C1.SC1=CC(Cl)=C(Cl)C=C1Cl Chemical compound CC(C)OC(=O)[C@H](C)N.CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)SC1=CC(Cl)=C(Cl)C=C1Cl.CCN(CC)CC.Cl.ClCCl.O=P(Cl)(Cl)OC1=CC=CC=C1.SC1=CC(Cl)=C(Cl)C=C1Cl FAHWHMJUIXXQLH-NMGLKSEGSA-N 0.000 description 1
- TTZHDVOVKQGIBA-BSKNERHYSA-N CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(C)(F)[C@H]1O)OC1=CC=CC=C1 Chemical compound CC(C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C(C)(F)[C@H]1O)OC1=CC=CC=C1 TTZHDVOVKQGIBA-BSKNERHYSA-N 0.000 description 1
- VWOBSQFNWHPELJ-OIJAAMDRSA-N CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=NC=C([N+](=O)[O-])C=C1 Chemical compound CC(C)OC(=O)[C@H](C)N[P@](=O)(OC1=CC=CC=C1)OC1=NC=C([N+](=O)[O-])C=C1 VWOBSQFNWHPELJ-OIJAAMDRSA-N 0.000 description 1
- DEBGJKGTBPYNOZ-FCWBHPHLSA-N CC.[2H]C([2H])(OP(=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1OC(N2C=CcnC2=O)[C@](C)(O)[C@@H]1O Chemical compound CC.[2H]C([2H])(OP(=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1OC(N2C=CcnC2=O)[C@](C)(O)[C@@H]1O DEBGJKGTBPYNOZ-FCWBHPHLSA-N 0.000 description 1
- IVTQUVCMEHIEQI-HAWMADMCSA-N CC1=CN=C(O[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)C=C1 Chemical compound CC1=CN=C(O[P@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)C=C1 IVTQUVCMEHIEQI-HAWMADMCSA-N 0.000 description 1
- LKZHYEKLOJEICM-UHFFFAOYSA-N FC1=C(F)C(F)=C(S)C(F)=C1F.O=C1C2=C(C=CC=C2)C(=O)N1O.O=C1CCC(=O)N1O.O=[N+]([O-])C1=CC=C(O)N=C1.O=[N+]([O-])C1=CC=C(S)C=C1.SC1=CC=C(Br)C=C1 Chemical compound FC1=C(F)C(F)=C(S)C(F)=C1F.O=C1C2=C(C=CC=C2)C(=O)N1O.O=C1CCC(=O)N1O.O=[N+]([O-])C1=CC=C(O)N=C1.O=[N+]([O-])C1=CC=C(S)C=C1.SC1=CC=C(Br)C=C1 LKZHYEKLOJEICM-UHFFFAOYSA-N 0.000 description 1
- FCMUIHNVCCWVHK-FBHOVVAXSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@@]1(N=[N+]=[N-])O[C@@H](N2C=CC(=O)NC2=O)[C@H](O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@@](F)(C([2H])([2H])[2H])[C@@H]1O.[2H]C1=CN([C@@H]2O[C@@](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)(N=[N+]=[N-])[C@@H](O)[C@H]2O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(F)C([2H])([2H])[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(F)C([2H])([2H])[2H])C(=O)NC1=O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@@]1(N=[N+]=[N-])O[C@@H](N2C=CC(=O)NC2=O)[C@H](O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@@](F)(C([2H])([2H])[2H])[C@@H]1O.[2H]C1=CN([C@@H]2O[C@@](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)(N=[N+]=[N-])[C@@H](O)[C@H]2O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(F)C([2H])([2H])[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(F)C([2H])([2H])[2H])C(=O)NC1=O FCMUIHNVCCWVHK-FBHOVVAXSA-N 0.000 description 1
- QCBCHYYBNQPRLB-CRMXMAHNSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(N)CC2([2H])[2H])[C@](C)(F)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(N)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(N)CC2([2H])[2H])[C@](C)(F)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(N)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O QCBCHYYBNQPRLB-CRMXMAHNSA-N 0.000 description 1
- TWEHSFCRKBUCFI-FPTKBCGYSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(N)CC2([2H])[2H])[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(O)CC2([2H])[2H])[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(N)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1([2H])CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(N)CC2([2H])[2H])[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(O)CC2([2H])[2H])[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(N)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1([2H])CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O TWEHSFCRKBUCFI-FPTKBCGYSA-N 0.000 description 1
- LKKZPHXZACGMEY-DGSYWANJSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(O)CC2([2H])[2H])[C@](C)(F)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(O)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C(=O)N=C(O)CC2([2H])[2H])[C@](C)(F)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(O)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(N)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)F LKKZPHXZACGMEY-DGSYWANJSA-N 0.000 description 1
- SWTBYUBBSCEPDJ-NBBGPXGPSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1=C([2H])N([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=C([2H])N([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@]1(O)C([2H])([2H])[2H].[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(O)C([2H])([2H])[2H])C(=O)NC1=O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=C(C)C(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1=C([2H])N([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=C([2H])N([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@]1(O)C([2H])([2H])[2H].[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(O)C([2H])([2H])[2H])C(=O)NC1=O SWTBYUBBSCEPDJ-NBBGPXGPSA-N 0.000 description 1
- AQPXGUUGWHAQLB-UNDDOVGQSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C2(CC2)[C@@H]1O.[2H]C1=CN([C@@H]2O[C@H](C(C)O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23CC3)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23C([2H])C3[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23CC3)C(=O)NC1=O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)C2(CC2)[C@@H]1O.[2H]C1=CN([C@@H]2O[C@H](C(C)O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23CC3)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23C([2H])C3[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)C23CC3)C(=O)NC1=O AQPXGUUGWHAQLB-UNDDOVGQSA-N 0.000 description 1
- SWTBYUBBSCEPDJ-OXIOIAJYSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@@](O)(C([2H])([2H])[2H])[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(O)C([2H])([2H])[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@@](O)(C([2H])([2H])[2H])[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])([2H])[C@@]1(O)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@]2(O)C([2H])([2H])[2H])C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=O SWTBYUBBSCEPDJ-OXIOIAJYSA-N 0.000 description 1
- NRPMFIRPRNPEBF-ONZQNIOZSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@H](OC)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CCNC2=O)[C@](C)(F)[C@@H]1O.[2H]C([2H])([2H])[C@@]1(F)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@H]1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@H]2OC)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@H](OC)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CCNC2=O)[C@](C)(F)[C@@H]1O.[2H]C([2H])([2H])[C@@]1(F)[C@H](O)[C@@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)O[C@H]1N1C=CC(=O)NC1=O.[2H]C1=CC(=O)NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@H]1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@H]2OC)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O NRPMFIRPRNPEBF-ONZQNIOZSA-N 0.000 description 1
- MDYBLSXGYRPIST-APHOLFOESA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(O)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])([2H])C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)C([2H])([2H])[2H])[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2CCC(O)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])([2H])C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)C([2H])([2H])[2H])[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1CC(O)=NC(=O)N1[C@@H]1O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O MDYBLSXGYRPIST-APHOLFOESA-N 0.000 description 1
- CQWMSMUSHWNAJV-HPMBHOJLSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(N)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(N)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1N CQWMSMUSHWNAJV-HPMBHOJLSA-N 0.000 description 1
- CLTFUQDFRBWZSW-UIJSKYADSA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(N)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(O)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(N)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(O)=NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N CLTFUQDFRBWZSW-UIJSKYADSA-N 0.000 description 1
- JEZMXEGHJSEUKY-LDVWPBJASA-N [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(O)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O Chemical compound [2H]C([2H])(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2NCC(O)=NC2=O)[C@](C)(F)[C@@H]1O.[2H]C1([2H])NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1([2H])NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O.[2H]C1NN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1N.[2H]C1NN([C@@H]2O[C@H](CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)N=C1O JEZMXEGHJSEUKY-LDVWPBJASA-N 0.000 description 1
- YWXVOHYVIYMMCA-FSBGJCLYSA-N [2H]C([2H])([2H])C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1=CN([C@@H]2O[C@H](C(C)O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)C([2H])([2H])[2H])[C@@H](O)[C@@]2(C)O)C(=O)NC1=O Chemical compound [2H]C([2H])([2H])C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC1=CC=CC=C1)[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(O)[C@@H]1O.[2H]C1=CN([C@@H]2O[C@H](C(C)O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)F)C(=O)NC1=O.[2H]C1=CN([C@@H]2O[C@H](C(O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)C([2H])([2H])[2H])[C@@H](O)[C@@]2(C)O)C(=O)NC1=O YWXVOHYVIYMMCA-FSBGJCLYSA-N 0.000 description 1
- OVTWEBSWFMQZKA-HVLSDTKKSA-N [2H]C1=C(C)C(=C)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O Chemical compound [2H]C1=C(C)C(=C)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O OVTWEBSWFMQZKA-HVLSDTKKSA-N 0.000 description 1
- BPLFEHXOHVVIKL-NGQQWRNLSA-N [2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O Chemical compound [2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O)[C@@H](O)[C@@]1(C)O BPLFEHXOHVVIKL-NGQQWRNLSA-N 0.000 description 1
- VCOPWPLZRNMNMZ-HEHMELRYSA-N [2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O Chemical compound [2H]C1=C(C)C(=O)NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O VCOPWPLZRNMNMZ-HEHMELRYSA-N 0.000 description 1
- AEHSYOFLDFHDOI-BKAFVODGSA-N [2H]C1=CC(OC)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CC(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)N(C)C Chemical compound [2H]C1=CC(OC)=NC(=O)N1[C@@H]1O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC2=CC=CC=C2)[C@@H](O)[C@@]1(C)O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CC(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)N(C)C AEHSYOFLDFHDOI-BKAFVODGSA-N 0.000 description 1
- OXJZPRUZSHVLHD-UMKKKCBSSA-N [2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)C(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(C)=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCCCC Chemical compound [2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)C(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(=O)CCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(C)=O.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OC(C)C.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCC.[2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)N=C1OCCCC OXJZPRUZSHVLHD-UMKKKCBSSA-N 0.000 description 1
- ZLSXKIOCSDDYMG-OEQYHZJQSA-N [2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=C Chemical compound [2H]C1=CN([C@@H]2O[C@H](C([2H])([2H])O[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3)[C@@H](O)[C@@]2(C)O)C(=O)NC1=C ZLSXKIOCSDDYMG-OEQYHZJQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/252,494 US20140309164A1 (en) | 2013-04-12 | 2014-04-14 | Deuterated nucleoside prodrugs useful for treating hcv |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361811464P | 2013-04-12 | 2013-04-12 | |
US14/252,494 US20140309164A1 (en) | 2013-04-12 | 2014-04-14 | Deuterated nucleoside prodrugs useful for treating hcv |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140309164A1 true US20140309164A1 (en) | 2014-10-16 |
Family
ID=50686233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/252,494 Abandoned US20140309164A1 (en) | 2013-04-12 | 2014-04-14 | Deuterated nucleoside prodrugs useful for treating hcv |
US14/252,290 Expired - Fee Related US9447132B2 (en) | 2013-04-12 | 2014-04-14 | Highly active nucleoside derivative for the treatment of HCV |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/252,290 Expired - Fee Related US9447132B2 (en) | 2013-04-12 | 2014-04-14 | Highly active nucleoside derivative for the treatment of HCV |
Country Status (11)
Country | Link |
---|---|
US (2) | US20140309164A1 (de) |
EP (2) | EP2984098A2 (de) |
JP (2) | JP2016518359A (de) |
KR (2) | KR20160003700A (de) |
CN (2) | CN105705511A (de) |
AU (2) | AU2014250762A1 (de) |
BR (2) | BR112015025716A2 (de) |
CA (2) | CA2909273A1 (de) |
ES (1) | ES2623287T3 (de) |
RU (2) | RU2015148010A (de) |
WO (2) | WO2014169280A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160016986A1 (en) * | 2014-07-21 | 2016-01-21 | Milind Deshpande | Stabilized nucleotides for medical treatment |
US20160176911A1 (en) * | 2014-12-19 | 2016-06-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
WO2018031818A3 (en) * | 2016-08-12 | 2018-05-11 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2480559T3 (da) | 2009-09-21 | 2013-08-05 | Gilead Sciences Inc | Fremgangsmåder og mellemprodukter til fremstillingen af 1'-cyano-carbanukleosid-analoger |
CR20170278A (es) | 2010-07-22 | 2017-09-29 | Gilead Sciences Inc | Métodos y compuestos para tratar infecciones virales por paramyxoviridae |
US10034893B2 (en) | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
CN106459004B (zh) | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
DK3160476T3 (da) * | 2014-06-24 | 2020-12-21 | Janssen Biopharma Inc | Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner |
JP2017522343A (ja) * | 2014-07-31 | 2017-08-10 | サンド・アクチエンゲゼルシヤフト | ホスホルアミデート類の合成 |
WO2016023522A2 (en) * | 2014-08-15 | 2016-02-18 | Merck Sharp & Dohme Corp. | Substituted phosphoramidate compounds and uses thereof |
WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CN107108676A (zh) * | 2014-09-15 | 2017-08-29 | 美迪维尔公司 | 用于制备非对映异构纯的磷酰胺酯前药的方法 |
TWI740546B (zh) | 2014-10-29 | 2021-09-21 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
CA2969372C (en) | 2014-12-15 | 2023-05-16 | Emory University | Phosphoramidates for the treatment of hepatitis b virus |
WO2016098123A2 (en) * | 2014-12-16 | 2016-06-23 | Laurus Labs Private Ltd | A recycling process for preparing (s)-2-[(substituted-phenoxy)-phenoxy- phosphorylamino] propionic acid isopropyl ester diastereomers |
SG11201705069YA (en) * | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
WO2016134053A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
WO2016134058A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
UA124966C2 (uk) | 2015-03-06 | 2021-12-22 | Атеа Фармасеутікалс, Інк. | <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ |
JP6743135B2 (ja) | 2015-09-02 | 2020-08-19 | アッヴィ・インコーポレイテッド | 抗ウィルス性テトラヒドロフラン誘導体 |
SG10202001878WA (en) | 2015-09-16 | 2020-04-29 | Gilead Sciences Inc | Methods for treating arenaviridae and coronaviridae virus infections |
US20170087174A1 (en) * | 2015-09-29 | 2017-03-30 | Janssen Pharmaceuticals, Inc. | Combination therapy regimen for treatment of hcv |
AU2016366310C1 (en) | 2015-12-09 | 2021-09-09 | Research Triangle Institute | Improved apelin receptor (APJ) agonists and uses thereof |
CN108473525A (zh) * | 2016-01-04 | 2018-08-31 | 上海长森药业有限公司 | 氘代HCV NS5b抑制剂核苷酸衍生物及其用途 |
KR20190057277A (ko) * | 2016-06-24 | 2019-05-28 | 에모리 유니버시티 | B형 간염 바이러스 치료용 포스포아미데이트 |
LU100724B1 (en) | 2016-07-14 | 2018-07-31 | Atea Pharmaceuticals Inc | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
CN107759632A (zh) * | 2016-08-19 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 一种手性磷酸酯的制备方法 |
EP3865136A1 (de) | 2016-09-07 | 2021-08-18 | ATEA Pharmaceuticals, Inc. | 2'-substituierte-n6-substituierte purinnukleotide zur behandlung des corona-virus |
CN109790125B (zh) | 2016-09-16 | 2022-07-05 | 研究三角协会 | 四氢异喹啉κ阿片拮抗剂 |
JP7104690B2 (ja) | 2016-10-12 | 2022-07-21 | リサーチ トライアングル インスティテュート | 複素環式アペリン受容体(apj)アゴニスト及びそれらの使用 |
CN108276463A (zh) * | 2017-01-06 | 2018-07-13 | 米文君 | 一类新的化合物及其用途 |
KR20230151050A (ko) | 2017-02-01 | 2023-10-31 | 아테아 파마슈티컬즈, 인크. | C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염 |
KR102460968B1 (ko) | 2017-03-14 | 2022-11-01 | 길리애드 사이언시즈, 인코포레이티드 | 고양이 코로나바이러스 감염의 치료 방법 |
WO2018204198A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
CN107987105B (zh) * | 2017-11-24 | 2019-10-01 | 无锡微色谱生物科技有限公司 | 一种可用于皮肤敷料的h2s给体化合物、海绵敷料和制备方法 |
KR102139340B1 (ko) | 2017-12-01 | 2020-07-29 | 주식회사 엘지생활건강 | 즉시 주름 개선 및 탄력 증진용 화장료 조성물 |
EP3706762A4 (de) | 2017-12-07 | 2021-09-01 | Emory University | N4-hydroxycytidin und derivate sowie antivirale verwendungen im zusammenhang damit |
TW202012001A (zh) | 2018-04-10 | 2020-04-01 | 美商亞堤製藥公司 | C型肝炎病毒(hcv)感染硬化之患者的治療 |
CN110835358B (zh) * | 2018-08-16 | 2022-08-05 | 上海复星星泰医药科技有限公司 | 一种索磷布韦中间体的制备方法 |
CN110221064A (zh) * | 2019-05-23 | 2019-09-10 | 南京农业大学 | 猪塞尼卡谷病毒elisa抗体检测方法及应用 |
CA3163424A1 (en) | 2020-01-27 | 2021-08-05 | Gilead Sciences, Inc. | Methods for treating sars cov-2 infections |
WO2021173713A1 (en) | 2020-02-27 | 2021-09-02 | Atea Pharmaceuticals, Inc. | Highly active compounds against covid-19 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN111233929B (zh) * | 2020-02-28 | 2023-02-28 | 成都阿奇生物医药科技有限公司 | 一种核苷类似物的氘代物及其制备方法和用途 |
JP2023516087A (ja) | 2020-03-12 | 2023-04-17 | ギリアード サイエンシーズ, インコーポレイテッド | 1’-シアノヌクレオシドを調製する方法 |
KR20220164784A (ko) | 2020-04-06 | 2022-12-13 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형 |
CN111467363A (zh) * | 2020-04-07 | 2020-07-31 | 中国科学院深圳先进技术研究院 | 索非布韦在制备预防和治疗冠状病毒的药物中的应用 |
TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
CR20220675A (es) | 2020-06-24 | 2023-02-15 | Gilead Sciences Inc | Análogos de nucleósido de 1´- ciano y usos de los mismos |
KR20230057411A (ko) | 2020-08-27 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스 감염 치료를 위한 화합물 및 방법 |
CN116217632A (zh) * | 2021-12-06 | 2023-06-06 | 广州谷森制药有限公司 | 一种氘代胞苷衍生物的制备方法 |
TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
EP4337667A1 (de) | 2022-07-21 | 2024-03-20 | Antiva Biosciences, Inc. | Zusammensetzungen und dosierformen zur behandlung von hpv-infektionen und hpv-induzierter neoplasie |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012465A1 (en) * | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US3792039A (en) | 1971-12-27 | 1974-02-12 | Miles Lab | Poly 2'-fluoro-2'-deoxyuridylic acid |
US5449664A (en) | 1988-11-21 | 1995-09-12 | Syntex (U.S.A.) Inc. | Antiviral agents |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
WO1994005813A1 (en) | 1992-09-10 | 1994-03-17 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Compositions and methods for treatment of hepatitis c virus-associated diseases |
US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
BR9407510A (pt) | 1993-09-17 | 1997-01-07 | Gilead Sciences Inc | Análogos de nucleotideo |
US5656745A (en) | 1993-09-17 | 1997-08-12 | Gilead Sciences, Inc. | Nucleotide analogs |
PL187107B1 (pl) | 1996-10-16 | 2004-05-31 | Icn Pharmaceuticals | L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6054576A (en) | 1997-10-02 | 2000-04-25 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA |
US6127535A (en) | 1997-11-05 | 2000-10-03 | Ribozyme Pharmaceuticals, Inc. | Nucleoside triphosphates and their incorporation into oligonucleotides |
US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6482932B1 (en) | 1997-11-05 | 2002-11-19 | Ribozyme Pharmaceuticals, Incorporated | Nucleoside triphosphates and their incorporation into oligonucleotides |
DK1045897T3 (da) | 1998-01-23 | 2002-05-13 | Newbiotics Inc | Enzymatisk katalyserede, terapeutiske midler |
US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
EA200601591A1 (ru) | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
BR0114837A (pt) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
WO2002057287A2 (en) | 2001-01-22 | 2002-07-25 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2002092006A2 (en) | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
WO2003068162A2 (en) | 2002-02-14 | 2003-08-21 | Pharmasset Ltd. | Modified fluorinated nucleoside analogues |
CA2484921A1 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
JP2005533817A (ja) | 2002-06-28 | 2005-11-10 | イデニクス(ケイマン)リミテツド | フラビウィルス科ウィルス感染治療用の修飾2′および3′−ヌクレオシドプロドラッグ |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
BR0312278A (pt) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2499036A1 (en) | 2002-09-24 | 2004-04-08 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
AU2003300901A1 (en) | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
ES2726998T3 (es) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
BRPI0415883A (pt) | 2003-10-27 | 2007-01-09 | Genelabs Tech Inc | compostos e composições de nucleosìdeo para o tratamento de infecções virais |
KR100570697B1 (ko) | 2004-09-24 | 2006-04-12 | 삼성에스디아이 주식회사 | 연료 전지 시스템 및 이에 사용되는 개질기 |
WO2006121820A1 (en) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Phosphoramidate prodrugs for treatment of viral infection |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
JP5461009B2 (ja) | 2005-06-08 | 2014-04-02 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 非ペプチド及びペプチドbdnfニューロトロフィン類似体を用いた神経細胞生存促進法 |
CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
US7888330B2 (en) | 2005-11-09 | 2011-02-15 | Wayne State University | Phosphoramidate derivatives of FAU |
US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
AU2007215114A1 (en) | 2006-02-14 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
WO2008005542A2 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc., | Antiviral phosphinate compounds |
EA017448B1 (ru) | 2006-07-13 | 2012-12-28 | Ачиллион Фармасьютикалз, Инк. | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
JP2010513484A (ja) | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
EP2097451A2 (de) | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Antichemokin-(ccl2, ccl3, ccl5, cxcl11, cxcl12) einzeldomänenantikörper |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
EP2124555B1 (de) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Nukleosidarylphosphoramidate für die behandlung von rna-abhängigen rna-virusinfektionen |
JP2010518015A (ja) | 2007-01-31 | 2010-05-27 | アリオス バイオファーマ インク. | 2−5aアナログ類およびそれらの使用方法 |
WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
EP1980568A1 (de) | 2007-04-13 | 2008-10-15 | Eberhard Karls Universität Tübingen | Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung |
GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2009058800A2 (en) | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
US20090176732A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma Inc. | Protected nucleotide analogs |
WO2009086201A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents |
EP3042660A3 (de) | 2008-04-15 | 2016-10-26 | RFS Pharma, LLC. | Nukleosidderivate zur behandlung von caliciviridae-infektionen, einschliesslich norovirus-infektionen |
TW201004632A (en) | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
AR073003A1 (es) | 2008-08-08 | 2010-10-06 | Scinopharm Taiwan Ltd | Proceso para preparar 5-azacitosina nucleosidos y sus derivados |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010030858A1 (en) | 2008-09-15 | 2010-03-18 | Enanta Pharmaceuticals, Inc. | 4'-allene-substituted nucleoside derivatives |
PA8852101A1 (es) | 2008-12-08 | 2010-07-27 | Medivir Ab | Nucleótidos uracil ciclopropílicos |
CA2746265A1 (en) | 2008-12-10 | 2010-06-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication |
SI2364309T1 (sl) | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals, Inc. | Novi 4-amino-4-oksobutanoil peptidi kot inhibitorji virusne replikacije |
MX2011007364A (es) | 2009-01-09 | 2012-02-28 | Univ Cardiff | Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales. |
BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
AU2010226466A1 (en) | 2009-03-20 | 2011-10-20 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
WO2010108135A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
JO3027B1 (ar) | 2009-05-14 | 2016-09-05 | Janssen Products Lp | نيوكليوسيدات يوراسيل سبيرواوكسيتان |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
TWI598358B (zh) * | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US20130085133A1 (en) | 2010-02-08 | 2013-04-04 | Sourthern Research Institute Office of Commercialization and Intellectual Prop. | Anti-viral treatment and assay to screenfor anti-viral agent |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
CN102858790A (zh) | 2010-03-31 | 2013-01-02 | 吉利德制药有限责任公司 | 核苷氨基磷酸酯 |
EP2552203B1 (de) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Verbindungen und zusammensetzungen zur behandlung von virusinfektionen |
EP2601202B1 (de) | 2010-08-04 | 2014-09-03 | Herbert Schott | Auf knochen gerichtete duplex-bisphosphonatwirkstoffe |
WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
AR083221A1 (es) | 2010-09-29 | 2013-02-06 | Univ Nac Quilmes | Proceso para producir dialquilfosfotriesteres de nucleosidos mediante transesterificacion enzimatica y desproteccion de los mismos para producir nucleosidos monofosfato |
ES2605433T3 (es) | 2010-11-10 | 2017-03-14 | Janssen Products, L.P. | Fosforamidatos de espironucleósido oxetánico uracílico |
PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
CA2819041A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
WO2012092484A2 (en) | 2010-12-29 | 2012-07-05 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
WO2012094248A1 (en) | 2011-01-03 | 2012-07-12 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
WO2012125900A1 (en) | 2011-03-16 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | 2'-allene-substituted nucleoside derivatives |
EP2691409B1 (de) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Verbindungen und zusammensetzungen zur behandlung von virusinfektionen |
WO2012142523A2 (en) | 2011-04-13 | 2012-10-18 | Gilead Sciences, Inc. | 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment |
EP2696681B1 (de) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-substituierte nukleosidderivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen |
US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
KR20140033446A (ko) | 2011-05-19 | 2014-03-18 | 알에프에스 파마 엘엘씨 | 바이러스 감염 치료용 퓨린 모노포스페이트 프로드럭 |
MX349079B (es) | 2011-05-27 | 2017-07-07 | Achillion Pharmaceuticals Inc | Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc. |
KR20140064765A (ko) | 2011-06-30 | 2014-05-28 | 스텔라 에이피에스 | Hcv 조합 치료 |
US9416154B2 (en) | 2011-07-13 | 2016-08-16 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
WO2013024155A1 (en) | 2011-08-17 | 2013-02-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection |
EA201490254A1 (ru) | 2011-08-24 | 2014-07-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Комбинированное лечение гепатита с |
EP2755983B1 (de) | 2011-09-12 | 2017-03-15 | Idenix Pharmaceuticals LLC. | Substituierte carbonyloxymethylphosphoramidatverbindungen und pharmazeutische zusammensetzungen zur behandlung von virusinfektionen |
US8951985B2 (en) | 2011-09-12 | 2015-02-10 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CN103781496A (zh) | 2011-09-16 | 2014-05-07 | 艾伯维公司 | 用于治疗hcv的方法 |
WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013066991A1 (en) | 2011-10-31 | 2013-05-10 | Inhibitex, Inc. | Crystalline solvates of nucleoside phosphoroamidates, their stereoselective preparation, novel intermediates thereof, and their use in the treatment of viral disease |
US20130244966A1 (en) | 2011-12-12 | 2013-09-19 | Catabasis Pharmaceuticals, Inc. | Fatty acid antiviral conjugates and their uses |
WO2013101552A1 (en) | 2011-12-28 | 2013-07-04 | Abbvie Inc. | Methods for treating hcv |
EP2797586A1 (de) | 2011-12-29 | 2014-11-05 | AbbVie Inc. | Feste zusammensetzungen mit einem hcv-hemmer |
WO2013133927A1 (en) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate] |
-
2014
- 2014-04-14 BR BR112015025716A patent/BR112015025716A2/pt not_active IP Right Cessation
- 2014-04-14 RU RU2015148010A patent/RU2015148010A/ru not_active Application Discontinuation
- 2014-04-14 WO PCT/US2014/034021 patent/WO2014169280A2/en active Application Filing
- 2014-04-14 JP JP2016507702A patent/JP2016518359A/ja not_active Ceased
- 2014-04-14 EP EP14724944.5A patent/EP2984098A2/de not_active Withdrawn
- 2014-04-14 CA CA2909273A patent/CA2909273A1/en not_active Abandoned
- 2014-04-14 CN CN201480033500.3A patent/CN105705511A/zh active Pending
- 2014-04-14 ES ES14722955.3T patent/ES2623287T3/es active Active
- 2014-04-14 US US14/252,494 patent/US20140309164A1/en not_active Abandoned
- 2014-04-14 RU RU2015148006A patent/RU2015148006A/ru not_active Application Discontinuation
- 2014-04-14 JP JP2016507703A patent/JP2016522172A/ja active Pending
- 2014-04-14 US US14/252,290 patent/US9447132B2/en not_active Expired - Fee Related
- 2014-04-14 KR KR1020157032200A patent/KR20160003700A/ko not_active Application Discontinuation
- 2014-04-14 CA CA2909270A patent/CA2909270A1/en not_active Abandoned
- 2014-04-14 AU AU2014250762A patent/AU2014250762A1/en not_active Abandoned
- 2014-04-14 EP EP14722955.3A patent/EP2984097B1/de active Active
- 2014-04-14 CN CN201480033503.7A patent/CN105377868A/zh active Pending
- 2014-04-14 AU AU2014250764A patent/AU2014250764A1/en not_active Abandoned
- 2014-04-14 WO PCT/US2014/034018 patent/WO2014169278A1/en active Application Filing
- 2014-04-14 KR KR1020157032206A patent/KR20160002896A/ko not_active Application Discontinuation
- 2014-04-14 BR BR112015025766A patent/BR112015025766A2/pt not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012012465A1 (en) * | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
US20130281686A1 (en) * | 2010-07-19 | 2013-10-24 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
US9090642B2 (en) * | 2010-07-19 | 2015-07-28 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9422323B2 (en) | 2012-05-25 | 2016-08-23 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
US9845336B2 (en) | 2012-05-25 | 2017-12-19 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
US10040814B2 (en) | 2012-05-25 | 2018-08-07 | Janssen Sciences Ireland Uc | Uracyl spirooxetane nucleosides |
US10301347B2 (en) | 2012-05-25 | 2019-05-28 | Janssen Sciences Ireland Unlimited Company | Uracyl spirooxetane nucleosides |
US10544184B2 (en) | 2012-05-25 | 2020-01-28 | Janssen Sciences Ireland Unlimited Company | Uracyl spirooxetane nucleosides |
US10774106B2 (en) | 2012-05-25 | 2020-09-15 | Janssen Sciences Ireland Unlimited Company | Uracyl spirooxetane nucleosides |
US20160016986A1 (en) * | 2014-07-21 | 2016-01-21 | Milind Deshpande | Stabilized nucleotides for medical treatment |
US20160176911A1 (en) * | 2014-12-19 | 2016-06-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9758544B2 (en) * | 2014-12-19 | 2017-09-12 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2018031818A3 (en) * | 2016-08-12 | 2018-05-11 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105377868A (zh) | 2016-03-02 |
US9447132B2 (en) | 2016-09-20 |
BR112015025766A2 (pt) | 2017-10-17 |
EP2984097B1 (de) | 2017-03-29 |
JP2016518359A (ja) | 2016-06-23 |
JP2016522172A (ja) | 2016-07-28 |
EP2984097A1 (de) | 2016-02-17 |
RU2015148006A (ru) | 2017-05-18 |
EP2984098A2 (de) | 2016-02-17 |
RU2015148006A3 (de) | 2018-08-01 |
AU2014250762A1 (en) | 2015-10-29 |
KR20160002896A (ko) | 2016-01-08 |
KR20160003700A (ko) | 2016-01-11 |
BR112015025716A2 (pt) | 2017-07-18 |
CA2909270A1 (en) | 2014-10-16 |
CN105705511A (zh) | 2016-06-22 |
RU2015148010A (ru) | 2017-05-15 |
CA2909273A1 (en) | 2014-10-16 |
AU2014250764A1 (en) | 2015-10-29 |
RU2015148010A3 (de) | 2018-04-28 |
WO2014169280A3 (en) | 2014-12-18 |
ES2623287T3 (es) | 2017-07-10 |
WO2014169280A2 (en) | 2014-10-16 |
US20140309189A1 (en) | 2014-10-16 |
WO2014169278A1 (en) | 2014-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9447132B2 (en) | Highly active nucleoside derivative for the treatment of HCV | |
US10092547B2 (en) | Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero- heteraphanes and metallocenes useful for treating HCV infections | |
US9125904B1 (en) | Biphenyl imidazoles and related compounds useful for treating HCV infections | |
US8835456B1 (en) | NS5A inhibitors useful for treating HCV | |
US20100029652A1 (en) | Combination Therapy For Treating Hepatitis C Infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACHILLION PHARMACEUTICALS INC., CONNECTICUT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DESHPANDE, MILIND;WILES, JASON ALLAN;HASHIMOTO, AKIHIRO;AND OTHERS;SIGNING DATES FROM 20140708 TO 20140721;REEL/FRAME:033360/0359 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |